Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
DAWNRAYS PHARMA: 2023 ANNUAL REPORT
DAWNRAYS PHARMA To Go Ex-Dividend On May 28th, 2024 With 0.065 HKD Dividend Per Share
March 25th - $DAWNRAYS PHARMA(02348.HK)$ is trading ex-dividend on May 28th, 2024. Shareholders of record on May 29th, 2024 will receive 0.065 HKD dividend per share on June 12th, 2024. The ex-div
Dawnrays' 2023 Profit Falls 9% on Lower Revenue
Dawnrays Pharmaceutical's (HKG:2348) attribrtuable profit fell 9% to 326 million yuan, or 0.2174 yuan per share, in 2023, from 358.1 million yuan, or 0.2389 yuan per share, in 2022, according to a Friday filing with the Hong Kong bourse.
Changes in Hong Kong stocks | Dongrui Manufacturing (02348) fell by more than 10%. Profit attributable to shareholders of $326 million in 2023 decreased by 8.95% year-on-year
Dongrui Manufacturing (02348) fell by more than 10%, down 12.88% at press time, to HK$1.15, with a turnover of HK$1.54 million.
Dongrui Pharmaceuticals (02348) will pay a final dividend of HK6.5 cents per share on June 12
Dongrui Pharmaceuticals (02348) announced that it will pay a final dividend of HK6.5 cents per share on June 12, 2024.
The annual profit attributable to owners of Dongrui Pharmaceuticals (02348.HK) was about 326 million yuan, a year-on-year decrease of about 9.0%
Gelonghui, March 22丨Dongrui Pharmaceutical (02348.HK) announced that for the year ended December 31, 2023, the company recorded revenue of about RMB 1.15 billion, a year-on-year decrease of about 9.9%. Profit attributable to owners of parent companies was approximately RMB 326 million, a year-on-year decrease of approximately 9.0%. The Board recommended a year-end dividend of HK$0.065 per share.
DAWNRAYS PHARMA: ANNOUNCEMENT OF THE ANNUAL RESULTSFOR THE YEAR ENDED 31 DECEMBER 2023
Dongrui Pharmaceuticals (02348.HK) plans to hold a board meeting on March 22 to approve annual results
Gelonghui, March 8, 丨 Dongrui Pharmaceutical (02348.HK) issued an announcement. The company's board of directors meeting will be held on March 22, 2024 (Friday) to approve (among other things) the publication of the annual results announcements of the company and its subsidiaries for the year ended December 31, 2023, and to consider the proposed payment of a final dividend (if any).
DAWNRAYS PHARMA: DATE OF BOARD MEETING
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm From Dawnrays; Akeso Shares Slide 3%
Akeso (HKG:9926) unit Akeso Biopharma agreed to purchase a 35% stake in AD Pharmaceuticals from Dawnrays Pharmaceutical (HKG:2348) unit Dawnrays Biotechnology Capital (Asia) for 267.4 million yuan, a
[Hong Kong Stock Connect] Kangfang Biotech (09926) buys 35% of Kangrong Oriental's shares involving RMB 267 million
Jinwu Financial News | An indirect wholly-owned subsidiary of Kangfang Biotech (09926) purchased 35% of Kangrong Oriental's shares. After completing the acquisition, Kangrong Oriental will become an indirect wholly-owned subsidiary of the company. The cost was RMB 267 million. Kangrong Oriental is an innovative biopharmaceutical company integrating the development, production and sale of antibody drugs. It was established in a joint venture in December 2016 in the form of technology and product injection by the buyer and capital injection by the seller. Kangrong Oriental closely follows the cutting edge of scientific development and focuses on the innovative development of innovative drugs and combination therapies for major diseases such as cardiovascular and oncology.
Dongrui Pharmaceuticals (02348) plans to sell 35% of Kangrong Dongfang's shares
Dongrui Pharmaceuticals (02348) issued an announcement. On February 8, 2024, Dongrui Biotech, a wholly-owned subsidiary of the company, and...
Dawnrays Pharmaceutical to Sell Entire 35% Stake in AD Pharmaceuticals for CNY267.39M
Dawnrays Pharmaceutical to Sell Entire 35% Stake in AD Pharmaceuticals for CNY267.39M
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
No Data